Showing 11-20 of 62 results for "".
Experts React to Latest Benzene Analysis
https://practicaldermatology.com/series/dermwire-tv/experts-react-to-latest-benzene-analysis/29810/In this week's DermwireTV, Practical Dermatology Editorial Board members provide their thoughts on the recent analysis examining benzene concentrations in BPO products; Johnson & Johnson seeks new indications for IL-23 inhibitor Tremfya; and the founder and CEO of Terns discusses plans to improvAll About Innovations at DERM2021
https://practicaldermatology.com/series/dermatology-education-foundation/all-about-innovations-at-derm2021/19965/Whether you’re a new or experienced learner in the dermatology PA/NP space, Sandri Johnson, FNP-BC, says the DERM2021 NP/PA CME Conference has something to offer. Attendees will learn about the latest innovations in the field.Attend High-Quality Sessions at DERM2021
https://practicaldermatology.com/series/dermatology-education-foundation/attend-high-quality-sessions-at-derm2021/19966/Sandri Johnson, FNP-BC says she’s looking forward to attending this year’s DERM2021 NP/PA CME Conference, interacting with colleagues face-to-face, and going to high-quality, educational sessions to learn about what’s new in dermatology.Rhofade Approved, Sun Leaves Acne Behind, Radiesse Turns 10
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-rhofade-approved-sun-leaves-acne-behind-radiesse-turns-10/18552/The FDA has approved Allergan's Rhofade (Oxymetazoline 1%) cream for the topical treatment of persistent facial erythema associated with rosacea in adults. New research from Olay in collaboration with personal genetics company 23andMe shows that taking care of the skin may be the key to looking upSunscreen Ratings, Long Live Skin Launches, SCALE Highlights
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-sunscreen-ratings-long-live-skin-launches-scale-highlights/18471/Consumer Reports says that one-third of sunscreens tested in its latest evaluation provided less than half of the SPF protection touted on the label. For its part, the American Academy of Dermatology is reminding patients that sunscreen ingredients are safe. The Environmental Working Group continuesPapa in at Valeant, J&J Acquires Neostrata, Celebrity Lip Envy
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-papa-in-at-valeant-j-j-acquires-neostrata-celebrity-lip-envy/18772/This edition of DermWireTV brings news that Joseph C. Papa has left Perrigo Company plc, a top five global over-the-counter consumer goods and pharmaceutical company, to take the helm as CEO at Valeant Pharmaceuticals. He will replace J. Micheal Pearson. Valeant also concluded its investigation arouDermWireTV: Inclusion in Derm; Amgen, Incyte, Janssen, Dermavant Updates; Klisyri Launch; More
https://practicaldermatology.com/topics/practice-management/dermwiretv-inclusion-in-derm-amgen-incyte-janssen-dermavant-updates-klisyri-launch-more/19901/For an article in Pediatric Dermatology, Linda Oyesiku, MPH, a student member of the Society for Pediatric Dermatology, describes historical obstacles to inclusion and highlights opportunities to expand representation and reduce bias in dermatology. Research conducted by The Martec Group using their- Johnson & Johnson Consumer to Acquire NeoStratahttps://practicaldermatology.com/news/johnson-johnson-consumer-to-to-acquire-neostrata/2458589/Johnson & Johnson Consumer, Inc. has entered into a definitive agreement to acquire NeoStrata Company, Inc. The acquisition will include NeoStrata's affiliates and parent company TriStrata, Incorporated, a privately-held compan
- EpigenCare Named as Johnson & Johnson Innovation Finalist in Skincare Challengehttps://practicaldermatology.com/news/epigencare-named-as-johnson-johnson-innovation-finalist-in-skincare-challenge/2457829/EpigenCare Inc., a personalized skincare startup company, is a finalist in Johnson & Johnson Innovation’s Digital Beauty Quickfire Challenge. The Challenge
- Johnson & Johnson Completes Acquisition of Yellow Jersey Therapeuticshttps://practicaldermatology.com/news/Johnson-johnson-completes-acquisition-yellow-jersey-therapeutics/2467362/Johnson & Johnson has successfully completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics, to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody being evaluated for the treatment of atopic dermatitis